Publications by authors named "Zoran Hasanbasic"

Claim this Profile
I
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Jean-François Korobelnik, Paolo Lanzetta, Sergio Leal, Frank G Holz, W Lloyd Clark, Zoran Hasanbasic

Ophthalmology· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.
Won Ki Lee, Tien Y Wong, Shih-Jen Chen, Xiaodong Sun, Chui Ming Gemmy Cheung, Zoran Hasanbasic

JAMA Ophthalmol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial.
Diana V Do, Charles C Wykoff, Sobha Sivaprasad, David M Brown, David S Boyer, Zoran Hasanbasic

Ophthalmology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.
Jean-François Korobelnik, Paolo Lanzetta, Charles C Wykoff, Tien Y Wong, Xin Zhang, Zoran Hasanbasic

Eye (Lond)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reported Rates of Intraocular Inflammation with Intravitreal Aflibercept Administered via Pre-Filled Syringe or from Vials in Clinical Practice Between 2012 and 2022.
Ursula Schmidt-Ott, Scott Fitzpatrick, Zoran Hasanbasic, Sergio Leal, Peter Morgan-Warren

Clin Ophthalmol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.
Nicole Eter, Zoran Hasanbasic, Georgios Keramas, Christine Rech, Helmut Sachs

Graefes Arch Clin Exp Ophthalmol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Joachim Wachtlin, Nicole Eter, Zoran Hasanbasic, Georgios Keramas, Christine Rech

Graefes Arch Clin Exp Ophthalmol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study.
Christoph Ehlken, Thomas Wilke, Ulrike Bauer-Steinhusen, Hansjürgen T Agostini, Zoran Hasanbasic

Retina· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS.
Carsten Framme, Nicole Eter, Thomas Hamacher, Zoran Hasanbasic, Claudia Jochmann

Ophthalmol Retina· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration: A Discrete Choice Experiment.
Sabrina Mueller, Hansjürgen Agostini, Christoph Ehlken, Ulrike Bauer-Steinhusen, Zoran Hasanbasic

Ophthalmology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis